从减肥到多种疾病的预防:构建超越mmo的预期贡献。

IF 4.7 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Obesity Pub Date : 2025-07-30 DOI:10.1002/oby.70017
Naveed Sattar
{"title":"从减肥到多种疾病的预防:构建超越mmo的预期贡献。","authors":"Naveed Sattar","doi":"10.1002/oby.70017","DOIUrl":null,"url":null,"abstract":"<p>Currently approved incretin-based therapies for weight loss, specifically semaglutide and tirzepatide, can induce 10% to 25% reductions in body weight. These “chemical shields” against the obesogenic environment not only facilitate satiety at lower caloric intake but also reduce the pervasive “food noise” described by many users, making it potentially easier to engage in other healthy lifestyle changes. These are important medicines coming at a time when obesogenic environments show little signs of being meaningfully reversed.</p><p>Importantly, the clinical effects of these weight loss therapies extend beyond weight reduction. Semaglutide has been shown to reduce cardiovascular events in people without diabetes, as demonstrated in the landmark SELECT trial [<span>1</span>]. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1RA), appears to offer even greater average weight loss and potentially additional metabolic benefits, though its cardiovascular impact remains to be confirmed.</p><p>The ongoing SURMOUNT-MMO trial described in this issue of <i>Obesity</i> [<span>2</span>] is designed to evaluate this question and much more. It is the pivotal placebo-controlled cardiovascular outcomes trial for tirzepatide in individuals without type 2 diabetes (T2D), following on from the soon to be reported SUPRASS CVOT (https://clinicaltrials.gov/study/NCT04255433) which tests the cardiovascular outcomes of tirzepatide versus an active comparator, dulaglutide, in people with T2D. SURMOUNT-MMO compares tirzepatide to placebo for a composite primary endpoint that includes a range of cardiovascular events, notably including heart failure—a cardiovascular condition more strongly associated with obesity than atherosclerotic outcomes.</p><p>Critically, however, in addition to the primary endpoint, SURMOUNT-MMO is also examining a series of important secondary outcomes [<span>2</span>]. These include the incidence of T2D, changes in kidney function via estimated glomerular filtration rate, and physical functioning, each representing somewhat different pathways through which obesity causes harm: metabolic, hemodynamic, and mechanical. Other secondary and tertiary outcomes include heart failure hospitalization, obesity-related liver outcomes, cancers linked to obesity, and all-cause hospitalization [<span>2</span>]. Consequently, this trial will offer an opportunity to assess both the broad direct and weight loss effects of tirzepatide in a controlled setting (Figure 1). Placebo-controlled randomized trials remain the gold standard for assessing both benefits and safety and are especially valuable for detecting outcomes that are relatively common. Even the best designed observational studies cannot provide this level of causal evidence.</p><p>Beyond clinical outcomes, health systems and policy makers are paying close attention to trials like SURMOUNT MMO due to economic implications. The current costs of incretin therapies are high. While deemed cost-effective by many authorities, they are not yet cost-saving for most health systems—especially when scaled to the hundreds of millions of people worldwide who might be eligible. Results from SURMOUNT-MMO could help refine cost-effectiveness models and potentially support broader reimbursement strategies.</p><p>There are reasons to be cautiously optimistic. Tirzepatide has shown mean weight losses approaching 20% in prior trials at the highest dose (15 mg), about 6% greater than what has been observed with semaglutide (2.4 mg) [<span>3</span>]. This level of weight loss has recently been associated with more favorable changes in triglycerides, LDL cholesterol, and systolic blood pressure than when weight losses are around 10%–15% or lower [<span>4</span>]. While such improvements suggest the potential for additional modest cardiovascular benefits with greater weight loss, we recently argued that the emphasis in weight loss trials must shift beyond traditional major adverse cardiovascular events and toward the broader range of obesity-related outcomes that weight loss may influence [<span>5</span>]. This is because there are presently many proven and potential ways to slow atherosclerotic processes but few other licensed options for large-scale sustained weight loss (Figure 1). Equally, health care systems are suffering from the rising prevalence of multiple obesity-related comorbidities, well beyond atherosclerotic cardiovascular disease. Hence, SURMOUNT MMO is a critically important trial in modern medicine.</p><p>Still, expectations should be tempered as the impact of GIP agonism (in this case combined with GLP-1RA activity) on cardiovascular outcomes is not known. Also, the population enrolled in SURMOUNT-MMO is older and includes more men and individuals with comorbidities, factors linked to smaller average weight loss. Additionally, use of incretin therapies in the placebo arm during the study period could reduce the observed treatment differences. Nevertheless, as weight is a primary driver of many of the outcomes being assessed, the trial is of critical importance. Tirzepatide is currently the most potent approved weight loss agent, and this trial could further establish its role across a wider spectrum of obesity prevention and treatment.</p><p>Finally, SURMOUNT-MMO will also provide essential data on individuals without preexisting cardiovascular disease or diabetes. If the trial meets expectations on outcome benefits and safety and drug costs decline over time, it is likely these therapies will be introduced earlier in people living with obesity, potentially altering the trajectory of chronic disease prevention on a population scale.</p><p>N.S. has consulted for and/or received speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GlaxoSmithKline, Hanmi Pharmaceuticals, Menarini-Ricerche, Metsera, Novartis, Novo Nordisk, Pfizer, and Roche; and received grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche outside the submitted work.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"33 9","pages":"1622-1624"},"PeriodicalIF":4.7000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70017","citationCount":"0","resultStr":"{\"title\":\"From Weight Loss to Multimorbidity Prevention: Framing the Anticipated Contributions of SURMOUNT-MMO\",\"authors\":\"Naveed Sattar\",\"doi\":\"10.1002/oby.70017\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Currently approved incretin-based therapies for weight loss, specifically semaglutide and tirzepatide, can induce 10% to 25% reductions in body weight. These “chemical shields” against the obesogenic environment not only facilitate satiety at lower caloric intake but also reduce the pervasive “food noise” described by many users, making it potentially easier to engage in other healthy lifestyle changes. These are important medicines coming at a time when obesogenic environments show little signs of being meaningfully reversed.</p><p>Importantly, the clinical effects of these weight loss therapies extend beyond weight reduction. Semaglutide has been shown to reduce cardiovascular events in people without diabetes, as demonstrated in the landmark SELECT trial [<span>1</span>]. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1RA), appears to offer even greater average weight loss and potentially additional metabolic benefits, though its cardiovascular impact remains to be confirmed.</p><p>The ongoing SURMOUNT-MMO trial described in this issue of <i>Obesity</i> [<span>2</span>] is designed to evaluate this question and much more. It is the pivotal placebo-controlled cardiovascular outcomes trial for tirzepatide in individuals without type 2 diabetes (T2D), following on from the soon to be reported SUPRASS CVOT (https://clinicaltrials.gov/study/NCT04255433) which tests the cardiovascular outcomes of tirzepatide versus an active comparator, dulaglutide, in people with T2D. SURMOUNT-MMO compares tirzepatide to placebo for a composite primary endpoint that includes a range of cardiovascular events, notably including heart failure—a cardiovascular condition more strongly associated with obesity than atherosclerotic outcomes.</p><p>Critically, however, in addition to the primary endpoint, SURMOUNT-MMO is also examining a series of important secondary outcomes [<span>2</span>]. These include the incidence of T2D, changes in kidney function via estimated glomerular filtration rate, and physical functioning, each representing somewhat different pathways through which obesity causes harm: metabolic, hemodynamic, and mechanical. Other secondary and tertiary outcomes include heart failure hospitalization, obesity-related liver outcomes, cancers linked to obesity, and all-cause hospitalization [<span>2</span>]. Consequently, this trial will offer an opportunity to assess both the broad direct and weight loss effects of tirzepatide in a controlled setting (Figure 1). Placebo-controlled randomized trials remain the gold standard for assessing both benefits and safety and are especially valuable for detecting outcomes that are relatively common. Even the best designed observational studies cannot provide this level of causal evidence.</p><p>Beyond clinical outcomes, health systems and policy makers are paying close attention to trials like SURMOUNT MMO due to economic implications. The current costs of incretin therapies are high. While deemed cost-effective by many authorities, they are not yet cost-saving for most health systems—especially when scaled to the hundreds of millions of people worldwide who might be eligible. Results from SURMOUNT-MMO could help refine cost-effectiveness models and potentially support broader reimbursement strategies.</p><p>There are reasons to be cautiously optimistic. Tirzepatide has shown mean weight losses approaching 20% in prior trials at the highest dose (15 mg), about 6% greater than what has been observed with semaglutide (2.4 mg) [<span>3</span>]. This level of weight loss has recently been associated with more favorable changes in triglycerides, LDL cholesterol, and systolic blood pressure than when weight losses are around 10%–15% or lower [<span>4</span>]. While such improvements suggest the potential for additional modest cardiovascular benefits with greater weight loss, we recently argued that the emphasis in weight loss trials must shift beyond traditional major adverse cardiovascular events and toward the broader range of obesity-related outcomes that weight loss may influence [<span>5</span>]. This is because there are presently many proven and potential ways to slow atherosclerotic processes but few other licensed options for large-scale sustained weight loss (Figure 1). Equally, health care systems are suffering from the rising prevalence of multiple obesity-related comorbidities, well beyond atherosclerotic cardiovascular disease. Hence, SURMOUNT MMO is a critically important trial in modern medicine.</p><p>Still, expectations should be tempered as the impact of GIP agonism (in this case combined with GLP-1RA activity) on cardiovascular outcomes is not known. Also, the population enrolled in SURMOUNT-MMO is older and includes more men and individuals with comorbidities, factors linked to smaller average weight loss. Additionally, use of incretin therapies in the placebo arm during the study period could reduce the observed treatment differences. Nevertheless, as weight is a primary driver of many of the outcomes being assessed, the trial is of critical importance. Tirzepatide is currently the most potent approved weight loss agent, and this trial could further establish its role across a wider spectrum of obesity prevention and treatment.</p><p>Finally, SURMOUNT-MMO will also provide essential data on individuals without preexisting cardiovascular disease or diabetes. If the trial meets expectations on outcome benefits and safety and drug costs decline over time, it is likely these therapies will be introduced earlier in people living with obesity, potentially altering the trajectory of chronic disease prevention on a population scale.</p><p>N.S. has consulted for and/or received speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GlaxoSmithKline, Hanmi Pharmaceuticals, Menarini-Ricerche, Metsera, Novartis, Novo Nordisk, Pfizer, and Roche; and received grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche outside the submitted work.</p>\",\"PeriodicalId\":215,\"journal\":{\"name\":\"Obesity\",\"volume\":\"33 9\",\"pages\":\"1622-1624\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-07-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.70017\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obesity\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/oby.70017\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/oby.70017","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

目前批准的以肠促胰岛素为基础的减肥疗法,特别是西马鲁肽和替西帕肽,可诱导体重减少10%至25%。这些抵御致肥环境的“化学屏障”不仅有助于在低热量摄入时获得饱腹感,而且还减少了许多用户描述的普遍存在的“食物噪音”,使其更容易参与其他健康生活方式的改变。这些重要的药物出现在导致肥胖的环境几乎没有明显逆转的迹象的时候。重要的是,这些减肥疗法的临床效果不仅仅是减轻体重。具有里程碑意义的SELECT试验[1]证明,Semaglutide可减少无糖尿病患者的心血管事件。tizepatide是一种双重葡萄糖依赖性胰岛素性多肽(GIP)和胰高血糖素样肽-1受体激动剂(GLP-1RA),似乎可以提供更大的平均体重减轻和潜在的额外代谢益处,尽管其对心血管的影响仍有待证实。本期《肥胖》杂志中描述的正在进行的SURMOUNT-MMO试验旨在评估这个问题以及更多的问题。这是替西肽在非2型糖尿病(T2D)患者中的关键安慰剂对照心血管结局试验,紧随其后的是即将报道的SUPRASS CVOT (https://clinicaltrials.gov/study/NCT04255433),该试验测试了替西肽与活性比较物dulaglutide在T2D患者中的心血管结局。SURMOUNT-MMO比较了替西肽和安慰剂的复合主要终点,包括一系列心血管事件,特别是心力衰竭——一种与肥胖比动脉粥样硬化结果更密切相关的心血管疾病。然而,重要的是,除了主要终点外,SURMOUNT-MMO还研究了一系列重要的次要结果。这些因素包括T2D的发病率、肾小球滤过率引起的肾功能变化和身体功能,每一项都代表着肥胖引起危害的不同途径:代谢、血流动力学和机械。其他二级和三级结局包括心力衰竭住院、肥胖相关的肝脏结局、肥胖相关的癌症和全因住院。因此,该试验将提供一个机会来评估替西帕肽在受控环境下的广泛直接和减肥效果(图1)。安慰剂对照随机试验仍然是评估疗效和安全性的黄金标准,对于检测相对常见的结果尤其有价值。即使是设计最好的观察性研究也无法提供这种程度的因果证据。除了临床结果之外,由于经济影响,卫生系统和政策制定者正在密切关注像SURMOUNT MMO这样的试验。目前肠促胰岛素治疗的费用很高。虽然许多当局认为它们具有成本效益,但对于大多数卫生系统来说,它们尚未节省成本,特别是在将其扩大到全世界可能符合条件的数亿人时。SURMOUNT-MMO的结果可以帮助完善成本效益模型,并可能支持更广泛的报销策略。我们有理由保持谨慎乐观。在先前的试验中,替西帕肽在最高剂量(15mg)下的平均体重减轻接近20%,比使用semaglutide (2.4 mg)[3]时所观察到的体重减轻约6%。这一水平的体重减轻最近与甘油三酯、低密度脂蛋白胆固醇和收缩压的有利变化有关,而不是体重减轻10%-15%或更低。虽然这些改善表明,随着体重的减轻,可能会有额外的适度心血管益处,但我们最近认为,减肥试验的重点必须从传统的主要心血管不良事件转向更广泛的肥胖相关结果,即体重减轻可能影响bb0。这是因为目前有许多已证实的和潜在的方法来减缓动脉粥样硬化过程,但很少有其他获得许可的大规模持续减肥选择(图1)。同样,卫生保健系统也面临着与肥胖相关的多种合并症患病率不断上升的问题,远远超出了动脉粥样硬化性心血管疾病。因此,SURMOUNT MMO是现代医学中一项至关重要的试验。尽管如此,由于尚不清楚GIP激动作用(在本例中与GLP-1RA活性相结合)对心血管结局的影响,期望应该有所缓和。此外,参与SURMOUNT-MMO的人群年龄较大,包括更多的男性和患有合并症的个体,这些因素与平均体重减轻幅度较小有关。此外,在研究期间,在安慰剂组使用肠促胰岛素治疗可以减少观察到的治疗差异。 然而,由于体重是许多评估结果的主要驱动因素,因此该试验至关重要。替西帕肽是目前最有效的被批准的减肥药,这项试验可以进一步确定它在更广泛的肥胖预防和治疗中的作用。最后,SURMOUNT-MMO还将提供无心血管疾病或糖尿病患者的基本数据。如果试验在结果效益和安全性方面符合预期,并且药物成本随着时间的推移而下降,这些治疗方法很可能会更早地应用于肥胖人群,可能会改变人群范围内慢性疾病预防的轨迹。曾为雅培、艾伯维、安进、阿斯利康、勃林格殷格翰、Carmot Therapeutics、礼来、葛兰素史克、韩美制药、美纳里尼- ricerche、Metsera、诺华、诺和诺德、辉瑞和罗氏提供咨询和/或获得演讲嘉宾荣誉;并获得了阿斯利康、勃林格殷格翰、诺华和罗氏等公司的资助。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

From Weight Loss to Multimorbidity Prevention: Framing the Anticipated Contributions of SURMOUNT-MMO

From Weight Loss to Multimorbidity Prevention: Framing the Anticipated Contributions of SURMOUNT-MMO

Currently approved incretin-based therapies for weight loss, specifically semaglutide and tirzepatide, can induce 10% to 25% reductions in body weight. These “chemical shields” against the obesogenic environment not only facilitate satiety at lower caloric intake but also reduce the pervasive “food noise” described by many users, making it potentially easier to engage in other healthy lifestyle changes. These are important medicines coming at a time when obesogenic environments show little signs of being meaningfully reversed.

Importantly, the clinical effects of these weight loss therapies extend beyond weight reduction. Semaglutide has been shown to reduce cardiovascular events in people without diabetes, as demonstrated in the landmark SELECT trial [1]. Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist (GLP-1RA), appears to offer even greater average weight loss and potentially additional metabolic benefits, though its cardiovascular impact remains to be confirmed.

The ongoing SURMOUNT-MMO trial described in this issue of Obesity [2] is designed to evaluate this question and much more. It is the pivotal placebo-controlled cardiovascular outcomes trial for tirzepatide in individuals without type 2 diabetes (T2D), following on from the soon to be reported SUPRASS CVOT (https://clinicaltrials.gov/study/NCT04255433) which tests the cardiovascular outcomes of tirzepatide versus an active comparator, dulaglutide, in people with T2D. SURMOUNT-MMO compares tirzepatide to placebo for a composite primary endpoint that includes a range of cardiovascular events, notably including heart failure—a cardiovascular condition more strongly associated with obesity than atherosclerotic outcomes.

Critically, however, in addition to the primary endpoint, SURMOUNT-MMO is also examining a series of important secondary outcomes [2]. These include the incidence of T2D, changes in kidney function via estimated glomerular filtration rate, and physical functioning, each representing somewhat different pathways through which obesity causes harm: metabolic, hemodynamic, and mechanical. Other secondary and tertiary outcomes include heart failure hospitalization, obesity-related liver outcomes, cancers linked to obesity, and all-cause hospitalization [2]. Consequently, this trial will offer an opportunity to assess both the broad direct and weight loss effects of tirzepatide in a controlled setting (Figure 1). Placebo-controlled randomized trials remain the gold standard for assessing both benefits and safety and are especially valuable for detecting outcomes that are relatively common. Even the best designed observational studies cannot provide this level of causal evidence.

Beyond clinical outcomes, health systems and policy makers are paying close attention to trials like SURMOUNT MMO due to economic implications. The current costs of incretin therapies are high. While deemed cost-effective by many authorities, they are not yet cost-saving for most health systems—especially when scaled to the hundreds of millions of people worldwide who might be eligible. Results from SURMOUNT-MMO could help refine cost-effectiveness models and potentially support broader reimbursement strategies.

There are reasons to be cautiously optimistic. Tirzepatide has shown mean weight losses approaching 20% in prior trials at the highest dose (15 mg), about 6% greater than what has been observed with semaglutide (2.4 mg) [3]. This level of weight loss has recently been associated with more favorable changes in triglycerides, LDL cholesterol, and systolic blood pressure than when weight losses are around 10%–15% or lower [4]. While such improvements suggest the potential for additional modest cardiovascular benefits with greater weight loss, we recently argued that the emphasis in weight loss trials must shift beyond traditional major adverse cardiovascular events and toward the broader range of obesity-related outcomes that weight loss may influence [5]. This is because there are presently many proven and potential ways to slow atherosclerotic processes but few other licensed options for large-scale sustained weight loss (Figure 1). Equally, health care systems are suffering from the rising prevalence of multiple obesity-related comorbidities, well beyond atherosclerotic cardiovascular disease. Hence, SURMOUNT MMO is a critically important trial in modern medicine.

Still, expectations should be tempered as the impact of GIP agonism (in this case combined with GLP-1RA activity) on cardiovascular outcomes is not known. Also, the population enrolled in SURMOUNT-MMO is older and includes more men and individuals with comorbidities, factors linked to smaller average weight loss. Additionally, use of incretin therapies in the placebo arm during the study period could reduce the observed treatment differences. Nevertheless, as weight is a primary driver of many of the outcomes being assessed, the trial is of critical importance. Tirzepatide is currently the most potent approved weight loss agent, and this trial could further establish its role across a wider spectrum of obesity prevention and treatment.

Finally, SURMOUNT-MMO will also provide essential data on individuals without preexisting cardiovascular disease or diabetes. If the trial meets expectations on outcome benefits and safety and drug costs decline over time, it is likely these therapies will be introduced earlier in people living with obesity, potentially altering the trajectory of chronic disease prevention on a population scale.

N.S. has consulted for and/or received speaker honoraria from Abbott Laboratories, AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, GlaxoSmithKline, Hanmi Pharmaceuticals, Menarini-Ricerche, Metsera, Novartis, Novo Nordisk, Pfizer, and Roche; and received grant support paid to his university from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche outside the submitted work.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Obesity
Obesity 医学-内分泌学与代谢
CiteScore
11.70
自引率
1.40%
发文量
261
审稿时长
2-4 weeks
期刊介绍: Obesity is the official journal of The Obesity Society and is the premier source of information for increasing knowledge, fostering translational research from basic to population science, and promoting better treatment for people with obesity. Obesity publishes important peer-reviewed research and cutting-edge reviews, commentaries, and public health and medical developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信